In a Johns Hopkins smoking cessation trial, Cathy, a lifelong smoker, successfully quit and has stayed smoke-free. This study highlights the potential of innovative methods in overcoming nicotine addiction.
Estalyn Walcoff was experiencing existential distress following a cancer diagnosis. She describes the transformative psychedelic experience she had during the NYU Psilocybin Cancer Anxiety Study and how it shifted her perspective on the situation.
This article examines the therapeutic potential of psilocybin for treating depression, anxiety, and other mental health conditions. It highlights the findings of clinical trials that show how psilocybin can induce profound, lasting changes in mood and behavior when combined with psychotherapy. These effects are attributed to the psychedelic’s ability to promote neuroplasticity, enhance emotional processing, and reduce rigid thinking. The review also discusses the safety profile of psilocybin and its role in personalized mental health treatments.
Shared how psilocybin helped her with PTSD from her time serving in the Middle East.
Lost 26 colleagues in the 9/11 attacks and wrote about how psilocybin helped him overcome depression and suicidality after years of suffering.
This article appeared on Pharma on January 13th this year. It summarizes that 2024 was a year of setbacks exemplified by the FDA’s rejection of MDMA as a depression treatment. However, many promising trials are on the horizon in 2025.
This article, published in 2023 in Psychedelic Medicine, establishes that investigations of the psychotherapy components of psychedelic-assisted therapy (PAT) have lagged behind other work. Years of research on different forms of psychotherapy reveal that one of the most important contributors to outcomes is the therapeutic alliance, a cooperative connection between clients and providers.
